The needs of the caregiver in the long-term treatment of Alzheimer disease

Alzheimer Disease and Associated Disorders
Roger Bullock

Abstract

The long-term well-being of caregivers should be included as part of the treatment of patients with Alzheimer disease (AD). Throughout the process of caring for patients with AD, caregivers frequently experience social, emotional, physical, and financial losses, which become more significant as the disease progresses. Minimizing these losses is a goal in the overall management of AD. Successful treatment of the patient has been shown to positively impact quality of life for the caregiver. Randomized, controlled studies of acetylcholinesterase inhibitors (AChEIs) have demonstrated the effectiveness of these agents in stabilizing cognitive function and delaying behavioral symptoms. Moreover, a decrease in the incidence of nursing home placement has been associated with this therapy. The growing burden of AD on families and society as a whole warrants the investigation of ways to minimize the impact of AD. AChEIs play an important role in this effort. Further studies are needed to more closely examine the impact of specific AChEIs on caregiver burden.

References

Jan 1, 1992·Journal of Clinical Epidemiology·M BaumgartenS Gauthier
Aug 1, 1990·The American Journal of Psychiatry·C SteeleM Folstein
Oct 1, 1987·The Gerontologist·R StoneJ Sangl
Sep 1, 1983·The Australian and New Zealand Journal of Psychiatry·P W Burvill, M W Knuiman
May 1, 1982·Comprehensive Psychiatry·W Katon
Aug 1, 1995·Clinical Pharmacology and Therapeutics·E C Clipp, M J Moore
Apr 1, 1994·The Gerontologist·M StommelB A Given
Aug 1, 1994·American Journal of Public Health·R L Ernst, J W Hay
Jan 1, 1993·Health Affairs·D P RiceE Segura
Jan 1, 1997·Alzheimer Disease and Associated Disorders·S H Ferris, A Kluger
Jan 1, 1997·International Psychogeriatrics·S GauthierL Gauthier
Jun 13, 1998·Journal of the American Geriatrics Society·M WeinerG F Anderson
Jul 1, 1998·International Journal of Geriatric Psychiatry·C DonaldsonA Burns
Jan 7, 1999·Alzheimer Disease and Associated Disorders·P J WhitehouseA Wimo
Apr 8, 1995·Journal of Aging and Health·W MaxP Fox
Sep 10, 1999·International Journal of Geriatric Psychiatry·M T González-SalvadorA C Barba
Sep 14, 1999·Journal of the American Geriatrics Society·E M GuttermanH Fillit
Jan 5, 2000·The British Journal of Psychiatry : the Journal of Mental Science·S Kavanagh, M Knapp
Jan 5, 2000·The American Journal of Psychiatry·J L Cummings
Apr 28, 2000·The American Journal of Psychiatry·C G LyketsosJ C Breitner
Sep 6, 2000·Dementia and Geriatric Cognitive Disorders·R Blesa
Nov 18, 2000·International Psychogeriatrics·H M FillitR L Brooks
Dec 13, 2000·International Journal of Geriatric Psychiatry·S BorsonA Dokmak
May 10, 2001·The International Journal of Neuropsychopharmacology·Alistair Burns
Nov 28, 2001·Journal of General Internal Medicine·K M LangaA M Fendrick
Oct 9, 2003·International Journal of Geriatric Psychiatry·Mary SanoShane Kavanagh

❮ Previous
Next ❯

Citations

Jun 23, 2012·Social Psychiatry and Psychiatric Epidemiology·Angel PadiernaJosé Ma Quintana
Dec 3, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Nathan Herrmann, Serge Gauthier
May 2, 2007·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Gary Naglie
Apr 6, 2006·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Howard H FeldmanUNKNOWN 2nd Canadian Conference on Antidementia Guidelines
Mar 7, 2012·Journal of Affective Disorders·Nerea GonzálezJosé M Quintana
Jul 22, 2009·Patient Education and Counseling·Alma AuDolores Gallagher-Thompson
Jul 8, 2008·Archives of Gerontology and Geriatrics·Chii Jun ChiouHsiu Hung Wang
Mar 16, 2013·Journal of Clinical Nursing·Rikke Madsen, Regner Birkelund
May 3, 2014·Nursing Forum·Sarah LlanqueMichael Caserta
Oct 22, 2005·Lancet Neurology·Ian McKeith, Jeffrey Cummings
Apr 23, 2016·The Gerontologist·Marita McCabeGemma Tatangelo
Jul 19, 2008·Epidemiologic Reviews·Jessica J JalbertKate L Lapane
Mar 15, 2005·Alzheimer Disease and Associated Disorders·Josep M ArgimonCarmen Cabezas
Feb 24, 2006·Alzheimer Disease and Associated Disorders·Roger Bullock
Nov 4, 2008·Alzheimer Disease and Associated Disorders·Gang WangSheng-di Chen
May 7, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Freddi Segal-GidanUNKNOWN California Workgroup on Guidelines for Alzheimer's Disease Management

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses
Marijean Buhse
Social Psychiatry and Psychiatric Epidemiology
José Gutiérrez-MaldonadoDavid J Kavanagh
European Psychiatry : the Journal of the Association of European Psychiatrists
B LowyckJ Peuskens
International Journal of Stroke : Official Journal of the International Stroke Society
H RigbyS Phillips
© 2022 Meta ULC. All rights reserved